DrugPatentWatch Database Preview
Alvogen Company Profile
What is the competitive landscape for ALVOGEN, and what generic alternatives to ALVOGEN drugs are available?
There is one US patent protecting ALVOGEN drugs.
There is one patent family member on ALVOGEN drugs in one country and one hundred and fourteen supplementary protection certificates in twelve countries.
Summary for Alvogen
| International Patents: | 1 |
| US Patents: | 1 |
| Tradenames: | 38 |
| Ingredients: | 35 |
| NDAs: | 45 |
| Patent Litigation for Alvogen: | See patent lawsuits for Alvogen |
Drugs and US Patents for Alvogen
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alvogen Malta | RIVASTIGMINE | rivastigmine | FILM, EXTENDED RELEASE;TRANSDERMAL | 204403-002 | Sep 3, 2015 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Alvogen Inc | ACETYLCYSTEINE | acetylcysteine | SOLUTION;INHALATION, ORAL | 203853-001 | Jun 21, 2012 | AN | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Alvogen Malta | RIVASTIGMINE | rivastigmine | FILM, EXTENDED RELEASE;TRANSDERMAL | 204403-001 | Sep 3, 2015 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Alvogen | ADALAT CC | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 020198-002 | Apr 21, 1993 | AB1 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Alvogen
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Alvogen Malta | ZESTORETIC | hydrochlorothiazide; lisinopril | TABLET;ORAL | 019888-002 | Jul 20, 1989 | 4,472,380 | ➤ Sign Up |
| Alvogen Malta | TENORMIN | atenolol | TABLET;ORAL | 018240-001 | Approved Prior to Jan 1, 1982 | 3,836,671 | ➤ Sign Up |
| Alvogen Malta | MACROBID | nitrofurantoin; nitrofurantoin, macrocrystalline | CAPSULE;ORAL | 020064-001 | Dec 24, 1991 | 4,772,473 | ➤ Sign Up |
| Alvogen | ADALAT CC | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 020198-002 | Apr 21, 1993 | 4,892,741 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for ALVOGEN drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 450 mg | ➤ Subscribe | 2013-02-28 |
Non-Orange Book US Patents for Alvogen
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,703,191 | Controlled-release pharmaceutical tablets | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Alvogen Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2008038155 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Alvogen Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C0022 | France | ➤ Sign Up | PRODUCT NAME: ESTRADIOL ANHYDRE DROSPIRENONE; REGISTRATION NO/DATE IN FRANCE: NL 28661 DU 20040316; REGISTRATION NO/DATE AT EEC: RVG 27505 DU 20021211 |
| 80016 | Netherlands | ➤ Sign Up | PRODUCT NAME: LEVOFLOXACINE, DESGEWENST IN DE VORM VAN EEN SOLVAAT, IN HET BIJZONDER LEVOFLOXACINE-HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 21810 - RVG 21812 19971209; FIRST REGISTRATION: GB 13402/0011 - 13402/0013 19970606 |
| C/GB04/032 | United Kingdom | ➤ Sign Up | PRODUCT NAME: ESTRADIOL, OPTIONALLY IN THE FORM OF A HYDRATE, TOGETHER WITH DROSPIRENONE; REGISTERED: NL RVG 27505 20021211; UK PL 00053/0341 20040310 |
| 00C/027 | Belgium | ➤ Sign Up | PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
